Abstract Library

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4081 The risk of venous thromboembolism in neuroendocrine neoplasms: A single center experience

Introduction: Neuroendocrine Neoplasms (NENs) are a very heterogeneous group of tumors. Venous thromboembolism (VTE) is a common complication in cancer patients and one of the leading causes of mortality. There is a lack of data regarding the incidence and the impact of VTE in patients with NENs.

Conference:

Presenting Author: Belabdi D

Authors: Belabdi D, Bala N, Bouferoum L, Ou M,

Keywords: Neuroendocrine neoplasm, Venous thromboembolism,

#4062 Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine neoplasms (NEN)

Introduction: VTE is a significant complication in oncology and one of the primary causes of cancer-related mortality. Few studies have addressed VTE in pts with NEN, with an estimated incidence of 7.5% in the literature. Nevertheless, there is no evidence from large datasets.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Gutierrez-Gordo M, Roca-Herrera M, García-Álvarez A, Serradell S,

Keywords: Thrombosis, Heparin, Splenic thrombosis,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,

#2145 Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience

Introduction: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms associated with paraneoplastic syndromes. Venous thromboembolism (VTE) is a frequent complication in neoplastic patients and it is associated with increased morbidity and mortality. To date, there have been no specific studies in NEN, except for glucagon-secreting tumors

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cavalcoli F

Authors: Cavalcoli F, Rossi R, Artoni A, Sciola V, Zilli A,

Keywords: GEP-NEt, paraneoplastic syndromes, Venous thromboembolism,